📰 Actengine News
Actengine News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Actengine. Real-time updates on events, politics, business and more.
May 2, 2023
Company to host conference calltoday, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203
August 23, 2022
IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics' proprietary CD8aß co-receptor engaging functional CD4 and CD8 T cells directed against PRAME Preclinical data with IMA203CD8
May 18, 2022
The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab1, a PD-1 immune checkpoint inhibitor
March 17, 2021
https://immatics.com/: Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine Cell Therapy Programs · cancer · Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell products · Houston, Texas and Tuebingen, Germany, March 17, 2021 - Immatics N.V.(NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immun...